Individually Talented,
Collectively Brilliant
Meet The Team
profile picture of amy locks
Amy Locks
CEO and CO-Founder
Amy leads Immobilase, combining technical expertise from her enzyme immobilisation PhD (UCL) with commercial experience at Pfizer and AstraZeneca. An award-winning entrepreneur (LBS Innovation to Market Pitch 2025) and featured in Nature Spotlight, she is also a graduate of the Conception X and Fifty Years' 5050 founder programs.
profile picture of amy locks
Pedro Lovatt Garcia
CTO and Co-Founder
Pedro is our Co-Founder and CTO, driving the company's technical strategy. He combines deep academic expertise from his PhD in Computational Enzyme Design at Imperial College London with hands-on experience as an expert in high-throughput screening for high-value chemicals. A seasoned entrepreneur, Pedro also brings invaluable experience from two previous synthetic biology startups.
profile picture of sir tony kouzarides
Prof. Sir. Tony Kouzarides
ADVISORY BOARD
Professor Tony Kouzarides is a leading authority in cancer biology and a serial biotech entrepreneur. Alongside his role as a Professor at the University of Cambridge, he co-founded Abcam (Acq. Danaher, $5.7bn) and STORM Therapeutics, and serves as the Director of the Milner Therapeutics Institute.
profile picture of sir tony kouzarides
Dr. Cam Watson
ADVISORY BOARD
Dr. Cam Watson is an Advisor with a robust background in life sciences strategy. He has driven strategic initiatives as Strategy Development Lead at Nuclera and Strategy Manager at LabGenius. Cam also brings consulting experience from his time as an Ex-LEK Life Sciences Specialist and currently advises several startups, including BoobyBiome.
Pfizer
5050 Accelerator
Astrazeneca
London business school
CenceptionX Accelerator
Picture of Founder and Advisor standing next to each other
Our Vision

Today’s biosynthesis is broken. Whole-cell fermentation wastes over 99% of its resources keeping cells alive, making thousands of nature's most valuable compounds far too expensive to produce. We are replacing this wasteful model with a new, radically efficient infrastructure for bio-production.

Instead of cellular factories, we build streamlined, cell-free systems. Our core immobilisation technology creates durable, reusable biocatalytic engines from only the essential molecular machinery, eliminating the massive energy overhead of cell growth and crushing the cost barriers that have stalled the industry.

Our mission is to make bio-production finally compete with chemical manufacturing on both cost and scale. By doing so we will unlock the sustainable production of natural compounds, once thought impossible to commercialise, building the industrial backbone for the coming bio-based economy.